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Abstract
Background: Anti-HIV-1 therapy depends upon multiple agents that target different phases of the viral replication
cycle. Recent reports indicate that plant and human DING proteins are unique in targeting viral gene transcription
as the basis of their anti-HIV-1 therapy.
Methods: Two cloned DING genes from Pseudomonas were transiently expressed in human cells, and effects on
NFκB-mediated transcription, HIV-1 transcription, and HIV-1 production were measured.
Results: Both DING proteins elevated NFκB-mediated transcription. In microglial cells, one protein, from P.
aeruginosa PA14, suppressed HIV-1 transcription; the other protein, from P. fluorescens SBW25, was inactive. The
PA14DING protein also reduces HIV-1 production in microglial cells.
Conclusions: Structural differences between the two DING proteins highlight regions of the PA14DING protein
essential to the anti-HIV-1 activity, and may guide the design of therapeutic agents.
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Background
DING proteins are characterised by a highly identical
DINGGG- amino acid sequence and are typically 30 –
40 kDa [1-4]. The first DING protein was found in the
synovial fluid of rheumatoid arthritis patients [5] and
since then, they have been identified in a range of different
organisms in a variety of contexts [3]. There is increasing
evidence that DING proteins have an ability to influence
human transcription and recently an ability to block
HIV-1 transcription and therefore viral replication (For
review see [3]).
DING proteins have been found to influence transcrip-
tion in a number of different situations. The synovial
stimulatory protein, secreted by rheumatoid arthritis
synovial fibroblasts, induces an inflammatory response
in synovial T-cells and also has a mitogenic effect on
synovial fibroblasts [5-7]. Although this does not directly
suggest DING proteins have an influence on human
transcription, these phenotypes are characteristic of an
increase in NFκB activity.
In cancer cachexia, proteolysis-inducing factor (PIF), a
24 kDa sulfated glycoprotein, induces the breakdown of
skeletal muscle leading to the loss of lean body mass in
cancer patients [8-10]. PIF binds to a membrane receptor,
a DING protein, and activates NFκB leading to the up-
regulation of pro-inflammatory cytokines IL-6, IL-8
and TNF-α and also the induction of the ubiquitin-
proteasome pathway [10,11].
Some DING proteins have been found to inhibit human
and viral transcription factors and exhibit powerful
repression of HIV-1 transcription and replication. The
first DING protein that was discovered to have anti-HIV
activity was isolated from the callus culture of St.
John’s Wort [12]. An initially obtained truncated clone,
p27SJ, inhibited HIV-1 transcription and replication in
monocyte-derived cells by inhibiting the human tran-
scription factor C/EBPβ and the viral trans-activator
protein, Tat. There is evidence of a direct interaction of
p27SJ with the two transcription factors resulting in
their functional inhibition [12,13]. A cDNA encoding a
full-length P38SJ protein was subsequently cloned and
found to have an even more powerful anti-HIV activity
[14]. Other DING proteins have also been found to have
anti-HIV activity. X-DING-CD4 (otherwise known as HIV
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resistant factor (HRF)) was isolated from the conditioned
medium of an HIV-1 resistant clone of T-lymphocytes
[15,16]. This protein is secreted by the HIV-1 resistant
cells and the addition of purified HRF to the culture
medium of non-resistant CD4+ T-cells makes these cells
also resistant to HIV [16]. The exact mechanism of its
action is unclear but there is evidence that it enters the
cell and inhibits the p50 subunit of NFκB, preventing its
binding to DNA leading to the inhibition of HIV-1
production [15]. It has recently been found that individ-
uals who have innate immunity to HIV infection have a
high level of DING mRNA expression [17]. This provides
support that the anti-HIV property of DING proteins is
effective in vivo.
The human phosphate binding protein (HPBP) isolated
from the plasma of human blood has recently been
found to have anti-HIV activity. Like X-DING-CD4,
HPBP can be added to the culture medium of primary
T-lymphocytes and primary macrophages resulting in
the inhibition of HIV-1 replication [18].
Despite the isolation of a number of DING proteins
that inhibit HIV-1 replication, their lack of known gene
sequences has been a hindrance to research. The full
amino acid sequence of HPBP has been identified from
the crystal structure and mass spectrometry [19] but
attempts to produce the recombinant protein through
the use of synthetic genes have been unsuccessful due to
insolubility.
In bacteria, the number of Pseudomonas DING genes,
of which products are secreted phosphate binding proteins
[20], has been gradually increasing in genome databases
as systematic sequencing of genomes progresses. Unlike
HPBP, recombinant Pseudomonas DING proteins can
be readily purified and share high sequence and structural
identity with eukaryotic DING proteins [21-23]. Further-
more, since DING proteins from Pseudomonas are highly
identical to those found in eukaryotes, we hypothesized
that they could be used as models to elucidate the func-
tion of eukaryotic DING proteins as transcriptional
regulators and explore their anti-HIV effects. By using
Pseudomonas DING proteins, we also aimed to address
whether they could in fact influence human transcription,
which transcription pathways they influenced and whether
they could inhibit HIV-1 transcription and replication.
The current treatment for HIV-1 involving combination
anti-retroviral therapy (cART) includes drugs that inhibit
viral entry, reverse transcription of the viral genome, inte-
gration into the host genome and the maturation of the
viral proteins. It is effective in reducing viral load but the
complete eradication of the virus and the threat of resist-
ance mutations continues to be a challenge [24-26]. It
is therefore essential to continue the development of
novel anti-HIV molecules that target other steps of the
viral life cycle.
Results
Bacterial DING proteins elevate NFκB-mediated
transcription
Previous studies indicate that DING proteins can affect
NFκB-mediated transcription [5,10,14]. In order to ensure
the intracellular localisation of Pseudomonas DING
proteins and test their effect on NFκB transcription in a
cell-based reporter assay, DING genes from P. aeruginosa
PA14 (PA14DING) and P. fluorescens SBW25 (PfluDING)
were cloned into human expression plasmids. The DING
expression constructs were co-transfected with an NFκB
limited-promoter reporter construct, pBIIXLuc and a
renilla luciferase internal control in HEK 293T cells. Cell
lysates were assayed for luciferase activities 48 hours
post-transfection. Both PA14DING and PfluDING signifi-
cantly stimulated NFκB activity with PA14DING having
the highest effect (Figure 1A).
In order to control for the over-expression of a Pseudo-
monas phosphate binding protein, PstS genes from P.
aeruginosa PA14 and P. fluorescens SBW25 were cloned
into a human expression vector and tested for their ef-
fect on NFκB mediated transcription. DING proteins
share a high structural identity with PstS proteins, which
are involved in acquiring phosphate when the environ-
mental phosphate level is low, and both proteins bind a
single inorganic phosphate molecule. Whilst DING and
PstS proteins are structurally and functionally similar,
their sequence identity is under 25%. The PstS expression
constructs were co-transfected with an NFκB limited-
promoter reporter construct, pBIIXLuc and a renilla lu-
ciferase internal control. The cell lysates were assayed
for luciferase activities 48 hours post-transfection. The PstS
proteins did not significantly increase NFκB-mediated
transcription providing support that the stimulatory ef-
fects of DING proteins were specific and not due to
experimental artefacts (Figure 1A).
Downstream effects of DING proteins
Since the DING-induced activation of NFκB was only
tested in a limited NFκB reporter construct, the effect
of DING proteins on a downstream component of the
NFκB pathway was investigated to determine whether the
DING-induced activation of NFκB had expected down-
stream consequences. HEK 293T cells were co-transfected
with the PA14DING and PfluDING expression constructs,
an IL-8 reporter construct and a renilla luciferase internal
control. The luciferase activities were assayed 48 hours
post-transfection. The DING proteins had a stimulatory
effect on IL-8 expression (13-fold and 28-fold higher
than for the empty vector control, for PfluDING and
PA14DING, respectively) providing evidence that the
DING-induced NFκB activation had downstream con-
sequences (Figure 1B). Control experiments with PstS
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expression constructs, in place of DING, showed no
significant elevation of the IL8 luciferase reporter.
In order to validate the specificity of the DING-induced
NFκB activation, Pseudomonas DING expression vectors
were co-transfected with the IκB super-repressor con-
struct, in which the phosphorylation sites were mutated
preventing its detachment from NFκB and subsequent
degradation. The IκB super-repressor completely abo-
lished DING-induced NFκB activation (Figure 1C).
Phosphate binding is not required for NF-κB activation
We next investigated the level of effect that the
phosphate-binding function of DING proteins had on
NFκB activation. Mutagenesis studies were performed
using PfluDING as a model. It has previously been
shown that the mutagenesis of just one of the eight
phosphate-binding residues of a recombinant Pseudo-
monas DING protein (T147N mutation) decreases the
affinity of phosphate binding of recombinant PfluDING by
95% [21]. Two additional phosphate-binding residues of
PfluDING, identified from its crystal structure, were
selected and replaced with residues (S32A and S145A)
that are unable to bind phosphate by site-directed muta-
genesis in order to minimise phosphate binding. A double
S32A/T147N mutation was also created to further elimin-
ate phosphate binding. The unaltered PfluDING expres-
sion vector and mutant constructs were transfected into
HEK 293T cells along with a NFκB reporter construct
(pBIIXLuc) and the renilla luciferase internal control.
The cell lysates were assayed for luciferase activities 48
hours post-transfection. The NFκB-stimulating levels
of the phosphate-binding mutants of PfluDING did not
significantly differ from that of the unmodified protein
(Figure 2A).
The PA14DING protein represses HIV-1 transcription
and HIV-1 production
The effect of Pseudomonas DING proteins on HIV-1
transcription was assessed in microglial cells which had
physiological relevance to HIV-1 infection. Microglial cells
were co-transfected with the HIV-1 LTR-luc reporter
vector, Tat, renilla luciferase and increasing amounts of
the PA14DING and PfluDING plasmids. The cell lysates
were assayed for luciferase activities 48 hours post-
A B
C D
Figure 1 DING proteins elevate NFκB mediated transcription. Plasmids expressing DING and PstS proteins were transfected into HEK 293T cells
along with a reporter plasmid containing: A) luciferase downstream of a promoter containing two NFκB binding sites (pBIIXLuc); B) a IL-8 reporter
containing the IL-8 gene promoter; C) pBIIXLuc with and without the IκB super-repressor expressing plasmid. The data were normalised with a third
plasmid containing Renilla luciferase under the control of a thymidine kinase promoter. The graphs are representative of at least 5 experiments with
each protein. RLU: relative light units. D) Western blots showing the expression of V5-tagged (i) PstS, (ii) DING proteins and β-actin controls in
transfected HEK 293T cells.
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transcription. Increasing amounts of the PA14DING ex-
pression vector correlated with the repression of HIV-1
transcription (Figure 3A). PfluDING did not have an effect
regardless of the dose (Figure 3B).
The Pseudomonas DING proteins were tested for their
effects on viral production. Initial experiments were done
using a pNL43 Δenv pseudovirus which had the viral
envelope genes replaced with a luciferase reporter gene.
Microglial cells were transfected with the pNL43 Δenv
genome and the PA14DING or PfluDING expression vec-
tor. The cell lysates were assayed for luciferase activity 48
hours post-transfection. PA14DING reduced HIV-1 pro-
duction by 38% (p < 0.05) whereas PfluDING did not have
a significant effect (Figure 4A).
The anti-HIV effect of PA14DING was verified by test-
ing its effect on the production of the wild type HIV-1
virus. Microglial cells were transfected with the wild type
pNL43 genome and PA14DING. The supernatant was
assayed for the level of the viral capsid protein, p24, 48
hours post-transfection. PA14DING repressed viral pro-
duction by ~43% (p < 0.05; Figure 4B). Taken all together
our work suggests strongly that PA14DING is a potent
inhibitor of HIV-1 replication.
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Figure 2 The effect of PfluDING and site-directed mutant
proteins on NFκB activity. A) HEK 293T cells were transfected
with pBIIXLuc (300~ng), renilla luciferase (80~ng) and PfluDING or
mutant expression constructs (420~ng). The cell lysates were
assayed for luciferase activities 48 hours post-transfection. The
phosphate-binding mutants did not have significantly different
effects on NFκB activity compared to the unmodified PfluDING.
Each point was done in triplicate and this graph is representative
of two separate experiments. The error bars represent standard
error. RLU: relative light units. B) Western blot showing the
expression of V5-tagged PfluDING, mutants and β-actin control in
transfected HEK 293T cells.
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Figure 3 Dose response of PfluDING and PA14DING on
Tat-mediated HIV-1 transcription in microglial cells. Microglial
cells were transfected with HIV-1 LTR-luc (280 ng), renilla luciferase
(100 ng), Tat (13 ng) and increasing amounts of the PfluDING or
PA14DING expression vectors (0–500 ng). The total amount of
transfected DNA was kept constant at 1 μg by the addition of the empty
pcDNA3.2/V5-DEST vector. The cell lysates were assayed for luciferase
activities 48 hours post-transfection. A) PA14DING inhibited Tat-mediated
HIV-1 transcription in a dose-dependent manner. B) PfluDING had no
effect regardless of the dose. The graphs are representative of at least
three separate experiments. Error bars represent standard error. RLU:
relative light units.
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Identification of putative PA14DING pharmacophores
PA14DING has a 74% sequence identity to PfluDING but
the former was the only one to have anti-HIV activity.
There were no significant differences in expression levels
of the two proteins and this raises the possibility that
peptide areas that are unique to PA14DING may be
responsible for blocking HIV-1 transcription and replica-
tion. The predicted 3D structure of PA14DING was gener-
ated using the LOMETS algorithm and this was compared
to the sub-angstrom crystal structure of PfluDING ([22];
Figure 5). The sequences that are unique to PA14DING
were highlighted on its predicted structure. Three sali-
ent differences are seen in external loops of the upper
globular domain, as the structures appear in Figure 5, and
identified by arrows (a and b). These regions correspond
to residues 162–167, and to 269–275, respectively, in the
PA14DING amino acid sequence. In this region, the
PfluDING molecule also has an additional loop (arrow c;
residues 223–238) which is not present in PA14DING.
Discussion
Previous studies with DING proteins from human disease
contexts such as rheumatoid arthritis and cancer cachexia
implicated DING proteins in having effects on NFκB-
mediated transcription. It was not possible to clone a hu-
man DING gene for investigation due to a lack of full hu-
man DING DNA or mRNA sequences. Although the full
amino acid sequence of the human phosphate-binding
protein was known [19], attempts to express recombinant
versions of the protein had been unsuccessful due to in-
solubility [3]. Whilst there was no previous compelling
evidence of bacterial DING proteins affecting human
transcription, the availability of full Pseudomonas DING
genes from genome databases provided an opportunity to
clone and directly assess the effect of DING proteins on
A B
Figure 4 The effect of DING proteins on HIV-1 production in microglial cells. A) Microglial cells were transfected with the pNL43 HIV-1 Δenv
pseudovirus genome (30 ng) and DING expression vectors (935 ng). The cell lysates were assayed for luciferase activity 48 hours post-transfection.
PA14DING reduced HIV-1 replication by ~40% (p < 0.05). PfluDING did not have a significant effect. This graph is representative of at least three
separate experiments. Error bars represent standard error. RLU: relative light units. B) Microglial cells were transfected with the full genome of
wildtype HIV-1 strain pNL43 (30 ng) and PA14DING (970 ng). Viral production was determined by measuring levels of the viral capsid protein p24
in the conditioned medium by ELISA 48 hours post-transfection. Serial dilutions of recombinant p24 were used to plot a standard curve which
was used to determine the absolute amount of p24 in the conditioned media. PA14DING inhibited HIV-1 replication by ~43% (p < 0.05). The
graph is representative of two separate experiments. Error bars represent standard error.
Figure 5 The unique areas of PA14DING in comparison to
PfluDING. The LOMETS predicted model of PA14DING was overlaid
with the crystal structure of PfluDING. The differences in sequence is
between the two proteins were mapped red on the PA14DING
model. Green: PA14DING model; Grey: PfluDING crystal structure.
Differences in external loops are highlighted by arrows (a; residues
162–167) and (b; residues 269–275). Arrow c represents a loop
present in PfluDING but absent in PA14.
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NFκB mediated transcription. This study has shown that
Pseudomonas DING proteins can significantly affect hu-
man transcription and be used as effective models for elu-
cidating the function of eukaryotic DING proteins,
including those isolated from human samples.
The direct stimulation of NFκB by DING proteins
supports previous studies in which NFκB activation was
directly observed, or implicated as the underlying mech-
anism causing observed phenotypic changes. In cancer
cachexia, the stimulation of NFκB may explain the re-
sulting activation of the ubiquitin-proteasome pathway
and the consequent degradation of muscle and hence
weight loss in cancer patients [9,10,27]. In rheumatoid
arthritis, NFκB activation and IL-8 expression would ex-
plain the activation of synovial T-cells and the mitogenic
stimulation of synovial fibroblasts [5,6]. P. aeruginosa
PA14 is a human pathogen, and its ability to express and
secrete a DING protein may elicit responses from host
cells; many inflammatory responses are initiated by NFκB
activation [28]. It is noteworthy that the stimulation of
NFκB activity is unrelated to the phosphate-binding ability
of PfluDING. We have not as yet created mutants of
the phosphate-binding residues in PA14DING, so can
make no definitive statement on the role of phosphate
binding in anti-HIV-1 activity. However, as discussed
below, the most prominent differences between the two
proteins are distant from the phosphate-binding sites.
Both PA14DING and PfluDING stimulate NF-kB
activity but PA14DING has a higher stimulatory effect
and is the only one of the proteins to inhibit HIV-1 tran-
scription and replication. The anti-HIV effect of the P.
aeruginosa DING protein is consistent with accumulating
evidence that eukaryotic DING proteins block HIV-1
transcription and replication [12-18,29]. It should be
pointed out that, in the case of X-DING-CD4, the anti-
HIV-1 effect is dependent upon the inhibition of NFκB
action [15,16], whereas our results indicate that these two
phenomena appear to be independent.
The two proteins are 74% identical in sequence and it
is possible that regions where the two proteins share
identical sequences are responsible for the stimulation of
NFκB and a region that is unique to PA14DING is re-
sponsible for attenuating HIV-1 transcription and pro-
duction. An overlay of the PfluDING crystal structure
and PA14DING model highlights areas that are unique
to PA14DING which may represent candidate areas that
are responsible for the anti-HIV activity (Figure 5), and
could form the basis for developing DING-based deriv-
atives. The external loops which form the most obvious
differences, are both in the domain which has been
identified as responsible for the mitogenic activity of
PfluDING towards human cells [21]. Although a truncated
DING protein corresponding to this domain is very poorly
soluble, the creation of full-length recombinant chimaeric
PfluDING proteins, incorporating each of these sequences
from PA14DING, should make it possible to identify the
structural elements responsible for anti-HIV-1 activity, in
combination with the use of site-directed mutants. Such
information would provide the starting-point for the de-
sign of synthetic peptides which could mimic this activity.
The results from this study strongly suggest that
PA14DING has a dual effect on HIV-1 transcription.
Indeed, our work suggests that (i) PA14DING might
activate the early cellular-dependant phase through
NFκB activation and (ii) shows that PA14DING inhibits
the Tat-dependent late phase [30]. Further investigation
will be needed to show that PA14DING is involved in
the activation of this early cell-dependent phase in micro-
glial cells, which represent the main HIV reservoir in the
central nervous system. Since it has been described previ-
ously that HIV-1 transcription and replication are acti-
vated through the NFκB pathway [31], it might be
possible to design a peptide derivative in order to re-
activate HIV-1 from these latent or quiescent infected
microglial cells. It will therefore be very exciting to identify
active PA14DING-derivatives involved in NFκB activation
and HIV-1 transcription. A combination of both could be
used in potential HIV-1 treatment strategies. The activa-
tion of HIV-1 transcription in the early phase could be
used to re-activate latent viral reservoirs which then can
be destroyed by cART [32]. In addition, as improving
cART continues to be important, the inhibiting properties
of PA14DING in the late phase of viral transcription
could be used to complement current cART by further
inhibiting HIV-1 replication and reducing viral load. A
combination of these effects will also decrease the like-
lihood of the development of cART resistant HIV-1 strains
[25]. The goal of this treatment strategy of reactivating
latent viral reservoirs followed by their destruction, is to
reduce the pool of latently-infected cells. Similarly,
strategies based on early treatment intervention would
aim to reduce the size of these latently-infected reservoirs.
Developing a treatment employing both strategies may
control HIV infection in patients, as observed in Elite
Controllers, and therefore might lead to a functional cure.
Conclusions
Both Pseudomonas DING proteins stimulate NFκB activity
but PstS, a related phosphate-binding protein, does not.
Mutation of the phosphate-binding site in a DING protein
does not affect NF-κB stimulation. PA14DING is more
effective as a stimulator of NFκB and is the only one of the
proteins to inhibit HIV-1 transcription and production.
This study along with the X-DING-CD4, p38SJ, and
HPBP studies provides evidence that DING-based deriv-
atives could be effective anti-HIV agents. The recent
identification of DING proteins originating from human
samples that block HIV-1 replication and the identifica-
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tion of individuals with high DING mRNA expression
correlating with HIV-1 resistance is evidence that DING
proteins may effectively block HIV-1 replication in vivo
[15-17]. The present study raises the possibility that
Pseudomonas DING proteins could be further developed
into anti-HIV molecules that would be easily administered
and complement current combination therapy regimes.
Methods
Cloning
gDNA samples were extracted from overnight cultures of
P. fluorescens SBW25 and P. aeruginosa PA14 using the
PureLink™ Genomic DNA Mini Kit (Invitrogen) following
the manufacturer’s guidelines. Primers were designed to
clone the entire open reading frames of the PfluDING,
PA14DING, Pflu PstS and PA14 PstS genes (excluding
the predicted signal sequences). Primers contained a
Kozak’s sequence (ACCATG) for mammalian expression,
the stop codon was removed to allow the expression of a
C-terminal V5 tag and were flanked with partial Gateway
recombination site tags. A nested PCR approach was used
to amplify the gene as previously described [33]. The final
PCR product was inserted into the donor plasmid
pDONR221 (Invitrogen) using the Gateway recombin-
ation system (Invitrogen) following the manufacturer’s
protocols. Recombinant clones were screened for the pres-
ence of inserts by restriction enzyme digestion and verified
by sequencing. A further recombination reaction and
sequence verification was undertaken to insert the
genes into pcDNA3.2/V5-DEST (Invitrogen) to produce
DING and PstS mammalian expression vectors under the
control of the CMV promoter (CMV-PfluDING, CMV-
PA14DING, CMV-PfluPstS, CMV-PA14PstS).
Site directed mutagenesis
Site-directed mutagenesis was undertaken using the
overlap PCR method as previously described [21]. The
resulting PCR products with appropriate mutations were
cloned into pcDNA 3.2/V5-DEST vectors using the
Gateway cloning system (Invitrogen).
Cell culture
The two cell lines HEK 293Tand microglial cells [34] were
grown in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum and 100 ug/ml
penicillin and streptomycin and glutamine.
Reporter assays
The reporter plasmids for NFκB [35] and HIV-1 LTR [12]
were kindly gifted by the authors of the respective papers.
The IL-8 reporter plasmid and IkB super-repressor vectors
were kindly gifted by Dr. Ashley Mansell.
HEK293T cells were transfected with reporter plas-
mids (expressing the firefly luciferase gene controlled by
promoters), experimental plasmids and an internal control
reporter encoding the Renilla luciferase gene (Promega)
using the Lipofectamine 2000 reagent (Invitrogen) follow-
ing the manufacturer’s protocol. Cells were assayed for
luciferase activities 48 hours after transfection using the
Dual Glo Luciferase Assay system (Promega) following the
manufacturer’s protocol. Firefly luciferase activity was
normalized against Renilla activity. The expression of
overexpressed proteins was detected using SDS-PAGE
and Western Blot analysis. Monoclonal anti-V5 antibodies
(Invitrogen) were used to detect the expression of DING
and PstS proteins co-expressed with C-terminal V5
tags and anti-β-actin antibodies (Sigma) were used to
detect β-actin.
HIV-1 production assay
Microglial cells were co-transfected with the HIV-1
pNL43 Δenv pseudovirus genome, in which the viral
envelope gene had been replaced with a luciferase gene
[36], with DING or PstS vectors using the calcium phos-
phate precipitation transfection method. Cells were assayed
for luciferase activity 48 hours after transfection using
the Luciferase Assay system (Promega) following the
manufacturer’s protocol and the data were normalized by
the total protein concentration.
For live HIV-1 production assays, microglial cells were
transfected with the HIV-1 pNL43 genome using the
calcium phosphate precipitation transfection method. The
conditioned medium was collected 48 hours after trans-
fection and levels of the viral capsid protein p24 were
quantified using the INNOTEST HIV Antigen mAb
ELISA kit following the manufacturer’s protocol.
In both cases we measured the luciferase activity or
quantified the p24 capsid protein to determine the
production of virus particles in a single round infection
assay.
3D structure
The 3D model of PA14DING was produced using the
LOMETS algorithm [37] and was viewed with Pymol.
The PfluDING crystal structure [22] was obtained from
the PDB.
Statistics
The Student’s t-test was used to determine the signifi-
cance of differences in data compared with the control.
Data was considered significant with a p-value < 0.05.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KS and AS conceived the study, participated in its design and coordination
and wrote the manuscript. AS undertook and participated in all experiments
including cloning, site-directed mutagenesis, NFκB reporter assays in HEK
293T cells, HIV-1 transcription reporter assays in microglial cells, HIV-1 pNL43
Suh et al. Virology Journal 2013, 10:234 Page 7 of 8
http://www.virologyj.com/content/10/1/234
Δenv pseudovirus reporter assays and HIV-1 pNL43 replication assays in
microglial cells. VLD carried out HIV-1 pNL43 replication assays in microglial
cells. OR and CS participated in the design of the study and drafting of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
AS and KS thank the Auckland Medical Research Foundation and the
University of Auckland for funding this project. We would also like to thank
the Royal Society of New Zealand and the Maurice and Phyllis Paykel Trust
for providing travel grants to Strasbourg. This work was supported by grants
to OR, CS and VLD from the Agence Nationale de Recherches sur le SIDA et
les hépatites virale (ANRS, France), Sidaction, the Institut Universitaire de
France (IUF).
Author details
1School of Biological Sciences, University of Auckland, Private Bag, Auckland
92019, New Zealand. 2Institut de Parasitologie et Pathologie Tropicale, EA 7292,
Université de Strasbourg, Strasbourg 67000, France. 3IUT Louis Pasteur, 1 allée
d'Athènes, Schiltigheim 67300, France.
Received: 4 March 2013 Accepted: 10 May 2013
Published: 15 July 2013
References
1. Berna A, Scott K, Chabriere E, Bernier F: The DING family of proteins:
ubiquitous in eukaryotes, but where are the genes? Bioessays 2009,
31:570–580.
2. Berna A, Bernier F, Chabriere E, Perera T, Scott K: DING proteins; novel
members of a prokaryotic phosphate-binding protein superfamily which
extends into the eukaryotic kingdom. Int J Biochem Cell Biol 2008, 40:170–175.
3. Berna A, Bernier F, Chabriere E, Elias M, Scott K, Suh A: For whom the bell
tolls? DING proteins in health and disease. Cell Mol Life Sci 2009,
66:2205–2218.
4. Berna A, Bernier F, Scott K, Stuhlmuller B: Ring up the curtain on DING
proteins. FEBS Lett 2002, 524:6–10.
5. Hain NA, Stuhlmuller B, Hahn GR, Kalden JR, Deutzmann R, Burmester GR:
Biochemical characterization and microsequencing of a 205-kDa synovial
protein stimulatory for T cells and reactive with rheumatoid factor
containing sera. J Immunol 1996, 157:1773–1780.
6. Adams L, Davey S, Scott K: The DING protein: an autocrine
growth-stimulatory protein related to the human synovial stimulatory
protein. Biochim Biophys Acta (BBA) Mol Basis Disease 2002, 1586:254–264.
7. Blass S, Schumann F, Hain NA, Engel JM, Stuhlmuller B, Burmester GR: p205
is a major target of autoreactive T cells in rheumatoid arthritis. Arthritis
Rheum 1999, 42:971–980.
8. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2002, 2:862–871.
9. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M:
Characterization of a cancer cachectic factor. Nature 1996, 379:739–742.
10. Todorov PT, Wyke SM, Tisdale MJ: Identification and characterization of a
membrane receptor for proteolysis-inducing factor on skeletal muscle.
Cancer Res 2007, 67:11419–11427.
11. Watchorn TM, Dowidar N, Dejong CHC, Waddell ID, Garden J, Ross JA: The
cachetic mediator proteolysis inducing factor activates NF-κB and STAT3
in human Kupffer cells and monocytes. Int J Oncol 2005, 27:1105–1111.
12. Darbinian-Sarkissian N, Darbinyan A, Otte J, Radhakrishnan S, Sawaya BE,
Arzumanyan A, Chipitsyna G, Popov Y, Rappaport J, Amini S, Khalili K:
p27SJ, a novel protein in St John's Wort, that suppresses expression of
HIV-1 genome. Gene Ther 2006, 13:288–295.
13. Darbinian N, Popov Y, Khalili K, Amini S: Creation of a bi-directional
protein transduction system for suppression of HIV-1 expression by
p27SJ. Antiviral Res 2008, 79:136–141.
14. Darbinian N, Gomberg R, Mullen L, Garcia S, White MK, Khalili K, Amini S:
Suppression of HIV-1 transcriptional elongation by a DING phosphatase.
J Cell Biochem 2011, 112:225–232.
15. Lesner A, Li Y, Nitkiewicz J, Li G, Kartvelishvili A, Kartvelishvili M, Simm M: A
soluble factor secreted by an HIV-1-resistant cell line blocks transcription
through inactivating the DNA-binding capacity of the NF-κB p65/p50
dimer. J Immunol 2005, 175:2548–2554.
16. Lesner A, Shilpi R, Ivanova A, Gawinowicz MA, Lesniak J, Nikolov D, Simm M:
Identification of X-DING-CD4, a new member of human DING protein
family that is secreted by HIV-1 resistant CD4(+) T cells and has anti-viral
activity. Biochem Biophys Res Commun 2009, 389:284–289.
17. Shilpi RY, Sachdeva R, Simm M: Cellular resistance to HIV-1 infection in
target cells coincides with a rapid induction of X-DING-CD4 mRNA:
Indication of the unique host innate response to virus regulated
through function of the X-DING-CD4 gene. Innate Immun 2011.
18. Cherrier T, Elias M, Jeudy A, Gotthard G, Le Douce V, Hallay H, Masson P,
Janossy A, Candolfi E, Rohr O, et al: Human-Phosphate-Binding-Protein
inhibits HIV-1 gene transcription and replication. Virol J 2011, 8:352.
19. Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F, Nicodeme
M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, et al: Serendipitous
discovery and X-ray structure of a human phosphate binding
apolipoprotein. Structure 2006, 14:601–609.
20. Zhang XX, Scott K, Meffin R, Rainey PB: Genetic characterization of psp
encoding the DING protein in Pseudomonas fluorescens SBW25.
BMC Microbiol 2007, 7:114.
21. Ahn S, Moniot S, Elias M, Chabriere E, Kim D, Scott K: Structure-function
relationships in a bacterial DING protein. FEBS Lett 2007, 581:3455–3460.
22. Liebschner D, Elias M, Moniot S, Fournier B, Scott K, Jelsch C, Guillot B,
Lecomte C, Chabriere E: Elucidation of the phosphate binding mode of
DING proteins revealed by subangstrom X-ray crystallography.
J Am Chem Soc 2009, 131:7879–7886.
23. Scott K, Wu L: Functional properties of a recombinant bacterial DING
protein: comparison with a homologous human protein. Biochim Biophys
Acta 2005, 1744:234–244.
24. Domingo P, Vidal F: Combination antiretroviral therapy. Expert Opin
Pharmacother 2011, 12:995–998.
25. Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O, Schwartz C:
Achieving a cure for HIV infection: do we have reasons to be optimistic?
J Antimicrob Chemother 2012, 67:1063–1074.
26. Shafer RW, Schapiro JM: HIV-1 drug resistance mutations: An updated
framework for the second decade of HAART. AIDS Rev 2008, 10:67–84.
27. Whitehouse AS, Tisdale MJ: Increased expression of the ubiquitin-
proteasome pathway in murine myotubes by proteolysis-inducing factor
(PIF) is associated with activation of the transcription factor NF-κB.
Br J Cancer 2003, 89:1116–1122.
28. Tripathi P, Aggarwal A: NF-κB transcription factor: a key player in the
generation of immune response. Curr Sci 2006, 90:519–531.
29. Darbinian N, Czernik M, Darbinyan A, Elias M, Chabriere E, Bonasu S, Khalili K,
Amini S: Evidence for phosphatase activity of p27SJ and its impact on the
cell cycle. J Cell Biochem 2009, 107:400–407.
30. Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene
transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003,
74:736–749.
31. Janabi N, di Stefano M, Wallon C, Hery C, Chiodi F, Tardieu M: Induction of
human immunodeficiency virus type 1 replication in human glial cells
after proinflammatory cytokines stimulation: effect of IFNγ, IL1β and
TNFα on differentiation and chemokine production in glial cells.
Glia 1998, 23:304–315.
32. Le Douce V, Herbein G, Rohr O, Schwartz C: Molecular mechanisms of HIV-1
persistence in the monocyte-macrophage lineage. Retrovirology 2010, 7:32.
33. Moreland N, Ashton R, Baker HM, Ivanovic I, Patterson S, Arcus VL, Baker EN,
Lott JS: A flexible and economical medium-throughput strategy for
protein production and crystallization. Acta Crystallogr D Biol Crystallogr
2005, 61:1378–1385.
34. Janabi N, Peudenier S, Heron B, Ng KH, Tardieu M: Establishment of human
microglial cell lines after transfection of primary cultures of embryonic
microglial cells with the SV40 large T antigen. Neurosci Lett 1995,
195:105–108.
35. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and
aspirin. Science 1994, 265:956–959.
36. Le Douce V, Colin L, Redel L, Cherrier T, Herbein G, Aunis D, Rohr O, Van Lint C,
Schwartz C: LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional
silencing. Nucleic Acids Res 2012, 40:1904–1915.
37. Wu S, Zhang Y: LOMETS: a local meta-threading-server for protein
structure prediction. Nucleic Acids Res 2007, 35:3375–3382.
doi:10.1186/1743-422X-10-234
Cite this article as: Suh et al.: Pseudomonas DING proteins as human
transcriptional regulators and HIV-1 antagonists. Virology Journal
2013 10:234.
Suh et al. Virology Journal 2013, 10:234 Page 8 of 8
http://www.virologyj.com/content/10/1/234
